Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments.
Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a number of strategic collaborations with leading research institutions.
Company Details
- Employees
- 7
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://alyspharma.com
Alys Pharmaceuticals Questions
Alys Pharmaceuticals's website is http://alyspharma.com
Alys Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/alys-pharmaceuticals
Alys Pharmaceuticals has
7 employees.
View email and phone details for 7
employees at Alys Pharmaceuticals.
Alys Pharmaceuticals's industry is
Biotechnology Research
Alys Pharmaceuticals's top competitors are
Latigo Biotherapeutics, Inc.,
Profoundbio,
Granular Therapeutics Ltd,
Neurona Therapeutics,
Piezo Therapeutics,
Medicxi,
Ottimo Pharma,
Sionna Therapeutics,
Aldena Therapeutics,
Firefly Bio.
Alys Pharmaceuticals's categories are Biotechnology Research
Alys Pharmaceuticals's founding year is 2024
